Schelker, Roland Christian <br/><br/>
Marked regression of myelofibrosis during reduced-dose dasatinib treatment in chronic myelogenous leukemia in accelerated phase.  [electronic resource] 

 -  Leukemia & lymphoma  2016 
 - 219-22 p.  digital 
<br/><br/> Publication Type: Case Reports; Letter 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.3109/10428194.2015.1045899  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--administration & dosage<br/>Bone Marrow--pathology<br/>Dasatinib--administration & dosage<br/>Humans<br/>Leukemia, Myeloid, Accelerated Phase--drug therapy<br/>Male<br/>Middle Aged<br/>Primary Myelofibrosis--drug therapy<br/>Protein Kinase Inhibitors--administration & dosage<br/>Treatment Outcome